trending Market Intelligence /marketintelligence/en/news-insights/trending/R4XlbsRX-B9Cc4YopMyRbA2 content esgSubNav
In This List

Allergan files application with US FDA for uterine fibroids treatment

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Allergan files application with US FDA for uterine fibroids treatment

The U.S. Food and Drug Administration accepted Allergan plc's new drug application for ulipristal acetate, an investigational drug to treat abnormal uterine bleeding in women with uterine fibroids.

Allergan expects the drug to be approved in the first half of 2018.

The company previously reported positive results from the second of two phase 3 clinical trials of ulipristal acetate.